Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Radiolabelled 14C-canagliflozin · 1 trial · 1 indication
Plasma concentrations of canagliflozin (JNJ-28431754) will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
Urine concentrations of canagliflozin (JNJ-28431754) will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
The total radioactivity excreted in the urine will be expressed as a percentage of the administered dose of canagliflozin (JNJ-28431754) and will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
The total radioactivity excreted in the feces will be expressed as a percentage of the administered dose of canagliflozin (JNJ-28431754) and will be used to determine pharmacokinetic parameters for canagliflozin (measurements describing how the body affects the drug).
The total radioactivity in blood will be used to determine pharmacokinetic parameters for canagliflozin (JNJ-28431754) (measurements describing how the body affects the drug).
The total radioactivity in plasma will be used to determine pharmacokinetic parameters for canagliflozin (JNJ-28431754) (measurements describing how the body affects the drug).
Concentrations of canagliflozin (JNJ-28431754) metabolites in plasma will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body).
Concentrations of canagliflozin (JNJ-28431754) metabolites in urine will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body).
Concentrations of canagliflozin (JNJ-28431754) metabolites in feces will be used to investigate the metabolism of canagliflozin (the way the drug is broken down in the body).
| Arm | Type | Description |
|---|---|---|
| Radiolabeled 14C-canagliflozin | EXPERIMENTAL | Each volunteer will receive a single dose of radiolabelled 14C-canagliflozin (14C-JNJ-28431754) on Day 1. |
| Name | Type | Description |
|---|---|---|
| Radiolabelled 14C-canagliflozin (14C-JNJ-28431754) | DRUG | A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1. |
Inclusion Criteria: * Body Mass Index (BMI) (weight \[kg\]/height \[m2\]) between 18 and 30 kg/m2 * Non-smoker Exclusion Criteria: * Exposure to radiation for professional or medical reasons (except dental x-rays and x-rays of thorax and bone skeleton, excluding spinal column) in the past 12 mont...
Radiolabelled 14C-canagliflozin is used in a clinical study to investigate the absorption, metabolism, and excretion of canagliflozin (JNJ-28431754) in healthy male volunteers. It is a small molecule being developed by Johnson & Johnson (JNJ) for research purposes in healthy individuals.
Johnson & Johnson (JNJ) is the developer of Radiolabelled 14C-canagliflozin. The drug is being studied in a Phase 1 clinical trial to understand how canagliflozin is absorbed, metabolized, and excreted in the body.
Radiolabelled 14C-canagliflozin is in Phase 1 clinical development. The single trial for this drug has been completed, and it is not yet approved for any use. It remains an investigational drug being studied in healthy volunteers.
Radiolabelled 14C-canagliflozin has one completed clinical trial, NCT01791231, titled "A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers." The trial enrolled 6 healthy male participants in Belgium and was not randomized or blinded.
Radiolabelled 14C-canagliflozin is a radiolabelled form of canagliflozin, also known as JNJ-28431754. It is used in research to track the absorption, metabolism, and excretion of canagliflozin in the body, as studied in healthy male volunteers.